These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 22761464)

  • 21. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
    Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
    Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
    Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.
    Iida S; Tobinai K; Taniwaki M; Shumiya Y; Nakamura T; Chou T
    Int J Hematol; 2016 Nov; 104(5):596-604. PubMed ID: 27460677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
    Jakubowiak AJ; Jasielec JK; Rosenbaum CA; Cole CE; Chari A; Mikhael J; Nam J; McIver A; Severson E; Stephens LA; Tinari K; Rosebeck S; Zimmerman TM; Hycner T; Turowski A; Karrison T; Zonder JA
    Br J Haematol; 2019 Aug; 186(4):549-560. PubMed ID: 31124580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
    Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
    Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
    San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
    J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
    Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
    Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carfilzomib: a second-generation proteasome inhibitor for the treatment of multiple myeloma.
    McBride A; Klaus JO; Stockerl-Goldstein K
    Am J Health Syst Pharm; 2015 Mar; 72(5):353-60. PubMed ID: 25694410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
    Berdeja JG; Gregory TK; Faber EA; Hart LL; Mace JR; Arrowsmith ER; Flinn IW; Matous JV
    Am J Hematol; 2021 Apr; 96(4):428-435. PubMed ID: 33421178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial.
    Maruyama D; Tobinai K; Chou T; Taniwaki M; Shumiya Y; Iida S
    Cancer Sci; 2018 Oct; 109(10):3245-3252. PubMed ID: 30058108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.
    Schroeder MA; Fiala MA; Huselton E; Cardone MH; Jaeger S; Jean SR; Shea K; Ghobadi A; Wildes T; Stockerl-Goldstein KE; Vij R
    Clin Cancer Res; 2019 Jul; 25(13):3776-3783. PubMed ID: 30952640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
    O'Connor OA; Stewart AK; Vallone M; Molineaux CJ; Kunkel LA; Gerecitano JF; Orlowski RZ
    Clin Cancer Res; 2009 Nov; 15(22):7085-91. PubMed ID: 19903785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
    Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
    Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
    Vij R; Siegel DS; Jagannath S; Jakubowiak AJ; Stewart AK; McDonagh K; Bahlis N; Belch A; Kunkel LA; Wear S; Wong AF; Wang M
    Br J Haematol; 2012 Sep; 158(6):739-48. PubMed ID: 22845873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.